Moody Aldrich Partners LLC Verona Pharma PLC Transaction History

Moody Aldrich Partners LLC

$425 Million
Q1 2025

A detailed history of Moody Aldrich Partners LLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Moody Aldrich Partners LLC holds 96,603 shares of VRNA stock, worth $7.29 Million. This represents 1.44% of its overall portfolio holdings.

Number of Shares

96,603

Previous 94,942 1.75%

Holding current value

$7.29 Million

Previous $4.41 Million 39.1%

% of portfolio

1.44%

Previous 0.93%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 28, 2025	BUY	$44.81 - $69.63 $74,429 - $115,655	1,661 Added 1.75%	96,603 $6.13 Million
Q4 2024 Jan 22, 2025	SELL	$28.71 - $47.02 $4.53 Million - $7.42 Million	-157,810 Reduced 62.44%	94,942 $4.41 Million
Q3 2024 Oct 22, 2024	SELL	$15.46 - $30.16 $667,763 - $1.3 Million	-43,193 Reduced 14.59%	252,752 $7.27 Million
Q2 2024 Jul 23, 2024	SELL	$11.48 - $17.02 $217,741 - $322,818	-18,967 Reduced 6.02%	295,945 $4.28 Million
Q1 2024 Apr 29, 2024	SELL	$15.3 - $20.24 $95,609 - $126,479	-6,249 Reduced 1.95%	314,912 $5.07 Million
Q4 2023 Jan 25, 2024	SELL	$11.94 - $20.47 $402,091 - $689,347	-33,676 Reduced 9.49%	321,161 $6.38 Million
Q3 2023 Nov 07, 2023	BUY	$16.3 - $22.09 $214,116 - $290,174	13,136 Added 3.84%	354,837 $5.78 Million
Q2 2023 Jul 28, 2023	SELL	$19.41 - $23.43 $193,498 - $233,573	-9,969 Reduced 2.83%	341,701 $7.22 Million
Q1 2023 Apr 27, 2023	BUY	$18.06 - $25.27 $2.36 Million - $3.3 Million	130,487 Added 59.0%	351,670 $7.06 Million
Q4 2022 Jan 23, 2023	SELL	$9.84 - $26.13 $66,971 - $177,840	-6,806 Reduced 2.99%	221,183 $0
Q3 2022 Oct 18, 2022	BUY	$4.14 - $13.59 $943,874 - $3.1 Million	227,989 New	227,989 $2.33 Million

Others Institutions Holding VRNA

# of Institutions

291

Shares Held

74.3M

Call Options Held

933K

Put Options Held

1.98M

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $4.6B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Moody Aldrich Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Moody Aldrich Partners LLC with notifications on news.

Account

Moody Aldrich Partners LLC Verona Pharma PLC Transaction History